Contraindications
- Severe kidney impairment (GFR <30 mL/min), including dialysis
- Severe hepatic impairment
- Strong CYP3A4 inhibitors, cyclosporine, grapefruit
- Left ventricular outflow obstruction; untreated heart failure; unstable angina or myocardial infarction within 1 month
- Pregnancy, breastfeeding, women of childbearing potential without contraception
- Hypersensitivity
Dosing: Adult
- Mild to moderate essential hypertension: 10 mg once daily at least 15 minutes before a meal; titrate gradually to 20 mg if needed (full effect may take about 2 weeks); maximum 20 mg/day
Dosing: Altered kidney function
Lercanidipine is a dihydropyridine calcium-channel blocker cleared by CYP3A4 metabolism; levels are about 70% higher in severe kidney impairment and dialysis. Unlike amlodipine, the European label contraindicates it at glomerular filtration rate (GFR) below 30 mL/min, including dialysis, and asks for caution when increasing to 20 mg in mild to moderate impairment. In peritoneal dialysis it can cloud the effluent. It has no US FDA label.
Kidney function measure: European summary of product characteristics (SmPC) uses glomerular filtration rate (GFR, mL/min) for the contraindication; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 10 mg once daily at least 15 minutes before a meal, preferably in the morning; may increase to 20 mg after about 2 weeks (SmPC).
- CrCl 30–59 mL/min
- Mild to moderate impairment: start with special care; 10 mg may be tolerated, but increase to 20 mg cautiously (SmPC).
- CrCl 15–29 mL/min
- Contraindicated: severe kidney impairment (GFR <30 mL/min), including dialysis (SmPC).
- CrCl <15 mL/min (not on dialysis)
- Contraindicated: severe kidney impairment (GFR <30 mL/min), including dialysis (SmPC).
- Hemodialysis (intermittent)
- Contraindicated in dialysis (SmPC). Use another calcium-channel blocker (e.g., amlodipine).
- Peritoneal dialysis
- Contraindicated in dialysis (SmPC). Can cause cloudy peritoneal effluent that mimics peritonitis.
- CRRT
- Contraindicated in severe kidney impairment (SmPC).
- Dialyzable? No: dialysis is unlikely to help in overdose (over 98% protein-bound) (SmPC).
- Monitoring Blood pressure; peripheral edema; heart rate. Avoid grapefruit, alcohol, strong CYP3A4 inhibitors and cyclosporine (contraindicated) (SmPC).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (October 2022). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established under 18 years (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 10 mg, 20 mg
- Tablet: 10 mg, 20 mg
Registered products in the Philippines
6 products registered with the Food and Drug Administration (FDA) Philippines list Lercanidipine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products6
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Hypecare 10Lercanidipine Hydrochloride | 10mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-18990 | Oct 14, 2031 | |
Hypecare 20Lercanidipine Hydrochloride | 20mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-18991 | Oct 14, 2031 | |
Lerlet 20Lercanidipine hydrochloride (as hemihydrate) | 20 mg Film-Coated TabletWhite Opaque PVC/Aclar -Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-15689 | Aug 29, 2029 | |
ZanidipLercanidipine | 10 mg TabletBlister Pack x 15's (Box of 30's) | RxVAT-exempt | Recordati Industria Chimica E Farmaceutica S.p.A.Italy | Zuellig Pharma CorporationImporter: Abbott Laboratories | DR-XY25482 | Dec 15, 2029 | |
ZanidipLercanidipine | 20 mg TabletOpaque PVC/Aluminum blister pack x 14's (Box of 28's) | RxVAT-exempt | Recordati Industria Chimica e Farmaceutica S.p.A.Italy | Zuellig Pharma Corp.Importer: Abbott Laboratories | DR-XY30908 | Jul 15, 2031 | |
(no brand name)Lercanidipine Hydrochloride | 10 mg Film-Coated TabletWhite Opaque PVC/Aclar-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-16829 | Jul 15, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin) | Avoid | Lercanidipine AUC up about 15-fold (ketoconazole). | Contraindicated. |
| Cyclosporine | Avoid | Both levels rise (lercanidipine about 3-fold). | Contraindicated. |
| Grapefruit or grapefruit juice | Avoid | Higher exposure. | Contraindicated. |
| CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital) | Adjust or monitor | Less effect. | Monitor blood pressure. |
| Simvastatin | Minor | Simvastatin AUC up 56%. | Give lercanidipine in the morning and simvastatin in the evening. |
| Digoxin | Adjust or monitor | Digoxin peak up about 33%. | Monitor for digoxin toxicity. |
| Metoprolol | Minor | Lercanidipine bioavailability down about 50%. | Dose adjustment may be needed. |
| Alcohol | Minor | More blood-pressure lowering. | Avoid. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Peripheral edema
- Headache, flushing
- Tachycardia, palpitations
Serious
- Angina or myocardial infarction (rare, isolated)
- Hypotension, syncope
- Angioedema
Monitoring parameters
- Blood pressure; peripheral edema; heart rate. Avoid grapefruit, alcohol, strong CYP3A4 inhibitors and cyclosporine (contraindicated) (SmPC). Kidney
- Blood pressure
- Edema
Pharmacokinetics
Key PK parameters
| Bioavailability | About 10% (fed; high first pass); a high-fat meal increases it about 4-fold |
|---|---|
| Time to peak | 1.5 to 3 hours |
| Half-life | 8 to 10 hours (effect lasts 24 hours) |
| Half-life in kidney failure (ESKD) kidney | Levels about 70% higher in severe impairment or dialysis |
| Protein binding | Over 98% (lower in severe kidney or liver disease) |
| Metabolism (CYP, transporters) | Extensive CYP3A4 |
| Active metabolites | None (no parent drug in urine or feces) |
| Renal excretion kidney | About 50% of dose in urine as metabolites |
| Dialyzability kidney | No (unlikely to help in overdose) |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Lecalpin 10 mg film-coated tablets SmPC (PA2315/186/001) [HPRA (Ireland) product information, October 2022; no US FDA label]. https://assets.hpra.ie/products/Human/27113/Licence_PA2315-186-001_03072025140350.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Accord Healthcare Ireland Ltd.. (2022). Lecalpin 10 mg film-coated tablets (lercanidipine hydrochloride) [Summary of product characteristics, licence PA2315/186/001; text revised October 2022]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/27113/Licence_PA2315-186-001_03072025140350.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .